Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG confirms FY 2014 guidance
Basilea Pharmaceutica AG:Confirms its unchanged guidance.Total operating expenses for 2014 are estimated at 8 to 9 million Swiss francs on average per month.The operating loss in 2014 is estimated at 4 to 5 million Swiss francs on average per month.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis
- Basilea Pharmaceutica AG submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
- Basilea Pharmaceutica AG announces isavuconazole received QIDP designation from U.S. FDA
- Basilea Pharmaceutica AG Isavuconazole receives orphan drug designations in Europe
Latest Key Developments in Biotechnology
- Matinas BioPharma Holdings Inc submits Investigational New Drug Application for Lead Product Candidate MAT9001 for treatment of severe hypertriglyceridemia
- Pharmacyclics Inc files supplemental new drug application for IMBRUVICA for Waldenstrom's Macroglobulinemia
- BBB Therapeutics BV appoints Jan van Heek as Chairman
- Galapagos announces favorable data for phase 1 inflammatory bowel disease drug
- Share this
- Digg this